A5035548614- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Advanced Breast Cancer Therapies
- Monoclonal and Polyclonal Antibodies Research
- Protein Degradation and Inhibitors
- Multiple and Secondary Primary Cancers
- Biosimilars and Bioanalytical Methods
- Frailty in Older Adults
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Treatment and Pharmacology
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Viral-associated cancers and disorders
- Advancements in Semiconductor Devices and Circuit Design
- Economic and Financial Impacts of Cancer
- Sarcoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Biomedical Ethics and Regulation
- Nutrition and Health in Aging
- Acute Lymphoblastic Leukemia research
- Eosinophilic Disorders and Syndromes
- CNS Lymphoma Diagnosis and Treatment
- Protein purification and stability
- Meta-analysis and systematic reviews
Medical College of Wisconsin
2023-2025
Roswell Park Comprehensive Cancer Center
2016-2023
Moffitt Cancer Center
2022-2023
University at Buffalo, State University of New York
2017-2020
Buffalo State University
2018
Cornell University
2016
Multiple chimeric antigen receptor (CAR) T-cell and bispecific antibody (bsAb) therapies have been approved, demonstrating impressive clinical efficacy in relapsed/refractory multiple myeloma (MM). Currently, these treatment share overlapping approval indications the space, highlighting importance of optimal selection sequencing to maximize efficacy. For patients previously unexposed T-cell–directed therapies, several factors should be weighed when both options are available. These include...
Abstract Recent studies demonstrating the feasibility of outpatient chimeric antigen receptor (CAR)–modified T-cell therapy administration are either restricted to CARs with 41BB costimulatory domains or use intensive at-home monitoring. We report outcomes all commercially available CD19- and B-cell maturation (BCMA)–directed CAR using a strategy no remote monitoring an early cytokine release syndrome (CRS) intervention strategy. Patients hematologic malignancies who received in setting...
To report the activity of venetoclax in patients with relapsed mantle cell lymphoma (MCL), we identified 81 treated monotherapy (n = 50, 62%) or combination a Bruton tyrosine kinase inhibitor (BTKi) 16, 20%), an anti-CD20 monoclonal antibody 11, 14%), other active agents at 12 US academic medical centers. Patients had high-risk disease features including Ki67 >30% (61%), blastoid/pleomorphic histology (29%), complex karyotype (34%), and TP53 alterations (49%), received median 3 prior...
Ibrutinib is a first-in-class small molecule inhibitor that has shown remarkable efficacy in the treatment of CLL. Current guidelines recommend lifelong administration at fixed daily dose 420 mg. Data from real-world studies indicate up to 17.5% patients discontinue ibrutinib due toxicity. Hypothetically, judicious reductions could result improved tolerance. Our objective was study impact on outcomes CLL treated with setting. We identified 70 Roswell Park Comprehensive Cancer Center between...
12052 Background: Multiple myeloma is a disease of older adults with median age at diagnosis 68 years (y). Patients (pts) receiving chimeric antigen receptor T-cell (CAR-T) therapy for relapsed/refractory MM (RRMM) often experience detrimental effects due to frailty, comorbidity, and cumulative toxicities. In this study, we evaluated the prevalence impact defined by simplified frailty score, (SFS; Facon et al, Leukemia 2020), immuno-nutritional status, using Glasgow-prognostic score (GPS;...
Health-related quality of life (HRQoL) outcomes are important in making clinical and policy decisions. This study aimed to examine the HRQoL reporting cancer drug trials leading Food Drug Administration (FDA) approvals. retrospective cohort analysed data for FDA approvals between July 2015 May 2020. Proportion included that reported HRQoL, latency approval first report data, outcomes, their correlation with OS (overall survival) PFS (progression-free were analysed. Of 233 associated 207...
The Glasgow prognostic score (GPS) and CAR-HEMATOTOX (CAR-HT) identify multiple myeloma (MM) patients at high risk for immune-mediated toxicity early mortality with cellular immunotherapy. However, their association outcomes in receiving T-cell redirecting bispecific antibodies (bsAb) is unclear. This multi-centre retrospective study examines the of baseline GPS CAR-HT scores 126 MM treated bsAb. Overall, 19% were identified as but did not experience increased or mortality. Conversely,...
Background Ofatumumab is a humanized type 1 anti‐CD20 monoclonal antibody. Preclinical studies show improved complement‐mediated cytotoxicity (CMC) compared to rituximab in mantle cell lymphoma (MCL). This study evaluates the safety and efficacy of combining ofatumumab with HyperCVAD/MA (O‐HyperCVAD) newly diagnosed MCL. Methods In this single‐arm phase 2 study, 37 patients were treated combination O‐HyperCVAD for 4 or 6 cycles, followed by high dose chemotherapy autologous stem transplant....